MIST PPF Study now enrolling
Learn More
About
Our Purpose
Our Team
Investors
Science
Our Approach
Inhaled Advantage
Publications
Pipeline
Overview
AP01
AP02
AP03
Patients & Caregivers
Commitment
Clinical Trials
Expanded Access Policy
Investors & Media
Press Releases
Events
Culture & Careers
Overview
Culture
Benefits
Job Opportunities
Contact
Differences in e-Lung biomarker scores between treatment groups in post-hoc analysis of the ATLAS inhaled pirfenidone solution (AP01) for IPF clinical trial
Peter M. George, et al.